Saturday 17 October 2026 Export ZTEKF’s income statement to Excel — free account

Zentek Ltd.

ZTEKF Healthcare Medical Instruments & Supplies

Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025. In the quarter to June 2026, revenue fell 95.4%, EPS was flat, free cash flow fell 254.6% and total debt rose 6.53%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.39 0.04 −9.30%

Follow ZTEKF

Alert me

Market cap: $62.3M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 1/9
Altman Z: −2.15
Beneish M: n/a
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 62.30

Revenue 0.12

Net Income (7.56)

Free Cash Flow (4.56)

Net Debt (10.68)

Current Ratio 4.65

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E —

P/S ratio 374.43

P/B ratio 2.47

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 27.28%

10-year low 10-year high

P/B against its own 10 years 35.57%

10-year low 10-year high

EV/Sales against its own 10 years 26.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3	0	1	12
Receivables	0	1	0	0
Inventory	1	1	0	0
Other	—	—	—	—
	5	3	2	13

	2024	2025	2026	Q'26
Payables	1	2	2	3
ST’ Debt	0	0	—	—
Other	—	—	—	—
	1	3	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	29.69%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(8.03%)	(19.37%)	(32.42%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	—	—	—	—	—
’26	0	0	0	0	0
’25	0	0	0	1	1
’24	—	0	0	0	0
’23	0	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(1)	—	—	—	—
’26	(1)	(1)	(1)	(1)	(4)
’25	(1)	(1)	(1)	(1)	(5)
’24	(1)	(2)	(1)	(1)	(6)
’23	(2)	(3)	(2)	(2)	(10)
’22	(1)	(2)	(2)	(2)	(6)
’21	0	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(1)	—	—	—	—
’26	1	(1)	(2)	(1)	(2)
’25	(1)	(1)	(1)	(1)	(5)
’24	(1)	(2)	(1)	(1)	(6)
’23	(3)	(3)	(2)	(3)	(12)
’22	(1)	(2)	(3)	(4)	(10)
’21	0	(1)	(1)	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.01)	—	—	—	—
’26	(0.01)	(0.02)	(0.01)	(0.03)	(0.07)
’25	(0.02)	(0.02)	(0.01)	(0.01)	(0.07)
’24	(0.02)	(0.02)	(0.02)	(0.02)	(0.09)
’23	(0.04)	(0.03)	(0.02)	(0.01)	(0.11)
’22	(0.02)	(0.26)	(0.02)	(0.04)	(0.34)
’21	0.00	0.00	(0.02)	(0.02)	(0.04)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	0.46	0.27	0.21	0.17	1.36	1.28	0.97	0.50	0.62	0.37	Analyst estimates 2027–2029 Powerpack
	High	0.93	0.65	0.47	2.94	5.95	4.12	1.80	1.59	1.84	1.10
People
People	Employees	—	—	—	—	—	25	29	24	17	10
	Revenue/emp, $m	—	—	—	—	—	0.01	0.00	0.00	0.04	0.01
Income, $m
Income, $m	Revenue	—	—	—	—	—	0	0	0	1	0
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	(8.52)	(1,071.51)	(1,010.41)	22.02	(1,018.89)
	EBT	(2)	(1)	(2)	(1)	(3)	(31)	(11)	(9)	(7)	(7)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(11,144.44)	(19,790.20)	(39,258.82)	(1,150.61)	(5,881.86)
	Net income	(2)	(1)	(2)	(1)	(3)	(10)	(11)	(9)	(7)	(7)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
	Earnings	(0.04)	(0.02)	(0.03)	(0.02)	(0.04)	(0.34)	(0.11)	(0.09)	(0.07)	(0.07)
	Cash flow	(0.02)	(0.01)	(0.01)	(0.01)	(0.02)	(0.07)	(0.10)	(0.06)	(0.04)	(0.03)
	Capex	(0.01)	(0.01)	(0.02)	(0.02)	(0.01)	(0.03)	(0.02)	0.00	0.00	0.01
	Free cash flow	(0.03)	(0.02)	(0.03)	(0.03)	(0.03)	(0.10)	(0.11)	(0.06)	(0.05)	(0.02)
	Book value	0.28	0.27	0.28	0.25	0.25	0.30	0.22	0.15	0.10	0.07
	Shares, m	62	63	67	77	84	92	103	101	103	106
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	0.00	4,297.12	182.31	467.03
	P/B	—	—	—	—	—	10.19	6.85	8.13	10.78	7.91
	EV/Sales	—	—	—	—	—	0.00	(662.34)	4,233.47	182.75	471.81
	EV/FCF	—	—	—	—	—	(27.36)	(13.09)	(18.72)	(24.65)	(23.04)
Cash, $m
Cash, $m	Operating cash flow	(1)	(1)	(1)	(1)	(1)	(6)	(10)	(6)	(5)	(4)
	Capex	(1)	0	(1)	(1)	(1)	(3)	(2)	0	0	1
	Free cash flow	(2)	(1)	(2)	(2)	(2)	(10)	(12)	(6)	(5)	(2)
Balance, $m
Balance, $m	Working capital	1	0	1	0	1	24	12	3	1	(1)
	Total debt	—	—	—	—	0	2	1	1	0	1
	Net debt	(1)	0	(1)	(1)	(2)	(20)	(7)	(2)	0	0
	Shareholders’ equity	17	17	19	19	21	28	23	15	11	7
Returns, %
Returns, %	ROA	(12.79)	(7.03)	(10.06)	(5.91)	(13.75)	(115.99)	(39.30)	(41.39)	(48.16)	(58.57)
	ROIC	(8.19)	(4.66)	(6.52)	(4.21)	(10.90)	(78.87)	(43.50)	(43.68)	(39.66)	(66.94)
	ROE	(12.85)	(7.07)	(10.23)	(6.05)	(14.61)	(127.62)	(43.14)	(45.74)	(56.47)	(79.91)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
STXS Stereotaxis Inc.	$105.2M	— (loss-making)	— (loss-making)	−12.82% (below 0%: shrinking)	n/m	+0.45% (above 0%: growing)	58.49%	(59.56%)	Compare
MBOT Microbot Medical Inc.	$63.8M	— (loss-making)	—	+1,047.62% (above 0%: growing)	n/m	−98.72% (below 0%: shrinking)	(266.80%)	(2,567.63%)	Compare
ZTEKF Zentek Ltd.	$62.3M	— (loss-making)	—	−95.36% (below 0%: shrinking)	n/m	−254.61% (below 0%: shrinking)	0.00%	0.00%
DXR Daxor Corporation	$59.6M	4.7×	7.6×	−27.62% (below 0%: shrinking)	n/m	−88.56% (below 0%: shrinking)	0.00%	0.00%	Compare
POCI Precision Optics Corp.	$47.7M	— (loss-making)	—	+41.95% (above 0%: growing)	n/m	−45.64% (below 0%: shrinking)	25.34%	(1.21%)	Compare
NEPH Nephros Inc.	$38.1M	23.4×	76.0×	+36.16% (above 0%: growing)	+450.00% (above 0%: growing)	−31.49% (below 0%: shrinking)	66.91%	20.16%	Compare
HBIO Harvard Bioscience, Inc.	$37.8M	— (loss-making)	— (loss-making)	+11.13% (above 0%: growing)	n/m	−123.43% (below 0%: shrinking)	55.57%	(4.30%)	Compare
MLSS Milestone Scientific, Inc.	$29.6M	— (loss-making)	— (loss-making)	+22.27% (above 0%: growing)	n/m	+66.68% (above 0%: growing)	67.24%	(37.37%)	Compare
Median of peers	$53.7M	—	—	+29.22%	—	−38.56%	57.03%	(20.83%)

All 55 Medical Instruments & Supplies stocks →

Zentek Ltd. (ZTEKF) key facts

Concern: Zentek Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $120,200.00, down 80.8% from fiscal 2025.
Zentek Ltd. (ZTEKF) is a Medical Instruments & Supplies company in the Healthcare sector.
As of October 16, 2026, ZTEKF traded at $0.39, a market capitalization of $62.3 million.
Return on equity was −79.9% and debt-to-equity 0.07.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −2.15 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.